d-psi-Ephedrine

1produits homologués
1 monographie
Syrup

Monographies de Santé Canada

1

Allégations santé approuvées

4
  • Used as a decongestant (for the common cold)
  • Temporarily relieves/For the temporary relief of cold/(and) flu symptoms such as nasal congestion/sinus congestion/stuffy nose/nasal stuffiness
  • Temporarily relieves/For the temporary relief of nasal congestion/sinus congestion/stuffy nose/nasal stuffiness (due to hay fever/allergic rhinitis/the common cold)
  • Nasal decongestant

Plages de doses approuvées

1
PopulationPlage de dosesFréquence
Adolescents 12-17 years, Adults 18 years and older60–240 milligramsper day

Mises en garde et contre-indications

9
cautionKeep out of reach of children. In case of overdose, call a poison control centre or get medical help right away (US FDA 2022; HC 2009).
cautionStop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or last for more than 7 days (US FDA 2022).
cautionStop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms are accompanied by a high fever that lasts longer than 3 days, the production of thick yellow/green phlegm, rash or a persistent headache.
cautionAsk a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Brinker 2010; CRN 2000; Carruthers-Czyzewski 1996; Mortimer 1977).
cautionAsk a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking any other cough and cold or weight control medications or prescription drugs, or products which contain caffeine or ephedrine (Brinker 2010; HC 2009; Mills and Bone 2005; Greenway et al. 2004; Naik and Freudenberger 2004).
cautionAsk a health care practitioner/health care provider/health care professional/doctor/physician before use if you have asthma, diabetes, glaucoma, heart disease, high blood pressure, kidney disease, difficulty urinating, thyroid disease, seizure disorders or any other serious medical condition (Ando et al. 2022; Ganesh et al. 2019; Brinker 2010; HC 2009; Eccles 2006; Jorge et al. 2006; Bensky et al. 2004; Williamson 2003; Blumenthal et al. 2000; Mills and Bone 2000; Carruthers-Czyzewski 1996).
contraindicationDo not use with a monoamine oxidase inhibitor (MAOI) or for 2 weeks after stopping the MAOI drug (US FDA 2022; Brinker 2010; Eccles 2006; Mills and Bone 2005; Blumenthal et al. 2000; Carruthers-Czyzewski 1996).
adverse_reactionStop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if you experience severe headache, confusion, visual changes/changes in vision, nervousness, dizziness, sleeplessness, difficulty or pain when urinating or allergic reactions (Ando et al. 2022; Chen 2022; US FDA 2022; Gewirtz et al. 2021; Hinduja 2020; Patel et al. 2020; Pilato 2020; Ducros 2012; Legriel et al. 2021; Mills and Bone 2005; Bensky et al. 2004; Blumenthal et al. 2000; Dickerson et al. 1978).
adverse_reactionStop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if any new symptoms appear.

Noms alternatifs

4
Pseudoephedrine(common)(1S,2S)-2-Methylamino-1-phenylpropan-1-ol(alphaS)-alpha-[(1S)-1-(Methylamino)ethyl]benzenemethanold-psi-Ephedrine

Quantités courantes dans les produits homologués

1
15 mg3 produits homologués

Vérifiez la conformité de votre produit contenant d-psi-Ephedrine

Validez votre formulation contre les monographies de Santé Canada et 1 produits homologués contenant d-psi-Ephedrine.

Analyser gratuitement